What's Happening?
The U.S. Senate has passed the Access to Critical Therapies for ALS Reauthorization Act (ACT for ALS Reauthorization Act) of 2026 with bipartisan support. This legislation, spearheaded in the House by Representatives Mike Quigley (IL-05) and Ken Calvert
(CA-41), and in the Senate by Senators Lisa Murkowski (R-AK) and Chris Coons (D-DE), aims to renew and expand programs established by the original 2021 ACT for ALS. The reauthorization will continue to advance scientific understanding of neurodegenerative diseases and facilitate access to promising new treatments for individuals living with Amyotrophic Lateral Sclerosis (ALS). The bill also codifies the Department of Health and Human Services’ (HHS) interpretation of Expanded Access Program eligibility guidelines and mandates the Food and Drug Administration (FDA) to develop a new 5-year Action Plan specifically for rare neurodegenerative diseases. The legislation has garnered endorsements from several key organizations, including I AM ALS, the Muscular Dystrophy Association, the ALS Association, and the ALS Network.
Why It's Important?
The reauthorization of the ACT for ALS is critically important for the ALS community and the broader landscape of neurodegenerative disease research in the U.S. ALS is a 100% fatal disease with no known cure, making continued federal funding and support for research and treatment access vital. This act ensures the continuation of programs that have already helped thousands of Americans access investigational treatments and has significantly boosted federal research funding. By codifying HHS's interpretation of Expanded Access Program eligibility, the bill provides clearer pathways for patients to receive experimental therapies. The requirement for the FDA to create a 5-year Action Plan for rare neurodegenerative diseases signifies a long-term commitment to addressing these challenging conditions, potentially accelerating the development of new treatments and cures. This bipartisan effort underscores a national commitment to tackling complex health challenges and offers hope to patients and their families.
What's Next?
The ACT for ALS Reauthorization Act now awaits the President's signature to officially become law. Once signed, the renewed programs from the 2021 ACT for ALS will continue, ensuring ongoing federal research funding and access to treatments for individuals with ALS. The FDA will be tasked with developing and implementing a new 5-year Action Plan for rare neurodegenerative diseases, which will guide future research and regulatory efforts in this area. Advocacy groups like I AM ALS are encouraging supporters to thank the Congressional champions who facilitated the passage of this legislation. The reauthorization is expected to lead to further investment in ALS research and continued efforts to improve treatment access, building on the infrastructure and successes achieved since the original act was signed into law.
Beyond the Headlines
The passage of the ACT for ALS Reauthorization Act highlights the profound impact of patient advocacy and bipartisan collaboration in addressing critical public health issues. The sustained efforts of organizations like I AM ALS, co-founded by Brian Wallach, demonstrate how community-driven movements can influence federal policy and secure significant legislative victories. This act not only provides tangible benefits in terms of research funding and treatment access but also sets a precedent for how government, researchers, industry, and patient communities can unite to combat devastating diseases. The focus on rare neurodegenerative diseases through a mandated FDA action plan suggests a growing recognition of the need for specialized strategies and resources for conditions that often receive less attention than more prevalent illnesses. This legislative success could inspire similar collaborative models for other rare and challenging diseases, fostering a more integrated and responsive healthcare ecosystem.
